Personalized mRNA Vaccine Immunogenic against PDAC
- PMID: 37163684
- DOI: 10.1158/2159-8290.CD-NB2023-0038
Personalized mRNA Vaccine Immunogenic against PDAC
Abstract
BioNTech's personalized mRNA vaccine, autogene cevumeran, elicited neoantigen-specific T cells in eight of 16 patients with surgically resected pancreatic ductal adenocarcinoma, leading to T-cell expansion in the bloodstream and delays in disease recurrence, according to phase I trial data. A randomized follow-up study is planned.
©2023 American Association for Cancer Research.
Comment on
-
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10. Nature. 2023. PMID: 37165196 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical